Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13286569 | 0.80 | TSHR (0.52) | TSHREPHX2ALDH1A1SMN1; SMN2PLA2G4A | |
| SCHEMBL21538522 | 0.75 | TSHR (0.61) | TSHREPHX2ALDH1A1SMN1; SMN2RECQL | |
| SCHEMBL13991881 | 0.72 | EPHX2 (0.44) | TSHREPHX2ALDH1A1SMN1; SMN2PLA2G4A | |
| SCHEMBL407248 | 0.71 | TSHR (0.61) | TSHREPHX2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL13993133 | 0.71 | TSHR (0.45) | TSHREPHX2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL18768785 | 0.71 | TSHR (0.54) | TSHREPHX2ALDH1A1SMN1; SMN2RECQL | |
| SCHEMBL18525833 | 0.70 | EPHX1 (0.61) | TSHREPHX2ALDH1A1RECQLLMNA | |
| SCHEMBL7670643 | 0.70 | TSHR (0.58) | TSHREPHX2ALDH1A1SMN1; SMN2RECQL | |
| SCHEMBL15044413 | 0.70 | TSHR (0.58) | TSHREPHX2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6581647 | 0.69 | TET2 (0.53) | TSHREPHX2ALDH1A1RECQLLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319065-A1 | Systemic and Intrathecal Effects of a Novel Series of Phospholipase A2 Inhibitors on Hyperalgesia and Spinal Pge2 Release | PLA2G4A, PLA2G4B, PLA2G2A | TSHR 4228/4885EPHX2 140/4885ALDH1A1 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.